Compare VECO & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VECO | HRMY |
|---|---|---|
| Founded | 1945 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 1994 | 2020 |
| Metric | VECO | HRMY |
|---|---|---|
| Price | $32.56 | $36.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $28.00 | ★ $51.33 |
| AVG Volume (30 Days) | 552.1K | ★ 691.5K |
| Earning Date | 02-11-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | 0.83 | ★ 3.17 |
| Revenue | $681,408,000.00 | ★ $825,944,000.00 |
| Revenue This Year | N/A | $23.11 |
| Revenue Next Year | $9.65 | $16.15 |
| P/E Ratio | $37.40 | ★ $11.60 |
| Revenue Growth | N/A | ★ 21.13 |
| 52 Week Low | $16.92 | $25.52 |
| 52 Week High | $34.45 | $40.93 |
| Indicator | VECO | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 67.77 | 46.46 |
| Support Level | $28.46 | $35.42 |
| Resistance Level | $29.58 | $37.79 |
| Average True Range (ATR) | 1.02 | 1.04 |
| MACD | 0.20 | -0.46 |
| Stochastic Oscillator | 93.59 | 30.38 |
Veeco Instruments Inc is a United States-based company engaged in designing, developing, and manufacturing thin-film process equipment, mainly used for producing electronic devices. The company focuses on semiconductor process equipment that addresses a range of challenging materials engineering problems for its customers. Its products include Laser Processing Systems, Lithography Systems, Ion Beam Systems, SiC CVD Systems, MOCVD Systems, Wet Processing Systems, MBE Technologies, Atomic Layer Deposition Systems, Physical Vapor Deposition Systems, Dicing and Lapping Systems, as well as Gas & Vapor Delivery Systems. The majority of the company's revenue is generated from sales to the Semiconductor Industry and within China.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.